Fujita Yohei, Hatazaki Masahiro, Fujimi Satoshi
Department of Diabetes and Endocrinology, Osaka General Medical Center, Osaka, JPN.
Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, JPN.
Cureus. 2024 Aug 7;16(8):e66373. doi: 10.7759/cureus.66373. eCollection 2024 Aug.
The number of severe cases of coronavirus disease 2019 (COVID-19) has been decreasing since the emergence of the Omicron variant at the end of 2021. COVID-19 has become a common infectious disease in Japan and was downgraded to a category five infectious disease on May 8, 2023. This study aimed to compare the impact of diabetes mellitus on in-hospital mortality in COVID-19 patients since COVID-19 became a common infectious disease.
We conducted a retrospective observational study using data from an advanced critical care center in Osaka, Japan. The study included 1,381 patients of COVID-19 admitted to the center between March 1, 2020, and May 7, 2023, before COVID-19 became a category five infectious disease in Japan. Individuals younger than 18 years and pregnant women were excluded. We divided the patients into two groups: pre- and post-Omicron epidemic groups. The primary endpoint of the study was the in-hospital mortality, and the prognostic impact of diabetes mellitus was compared between the groups.
The Kaplan-Meier curve showed a significantly lower rate of in-hospital mortality in the post-Omicron epidemic group than in the pre-Omicron epidemic group. The hazard ratio (HR) was 1.83 (95% CI, 1.36-2.50; p < 0.0001). Patients with diabetes mellitus had higher in-hospital mortality in both the pre- and post-Omicron epidemic groups; their HRs were 1.39 (95% CI, 1.21-1.59; p < 0.0001) and 1.45 (95% CI, 1.15-1.83; p = 0.0012), respectively. Diabetes mellitus had no significant interaction effect on the association between the post-Omicron epidemic and in-hospital mortality (p for interaction = 0.2154).
Diabetes mellitus may continue contributing to COVID-19 in-hospital mortality in the future, as the Omicron sub-strain may still be prevalent.
自2021年底奥密克戎变异株出现以来,2019冠状病毒病(COVID-19)重症病例数一直在下降。COVID-19在日本已成为一种常见的传染病,并于2023年5月8日降级为五类传染病。本研究旨在比较自COVID-19成为常见传染病以来,糖尿病对COVID-19患者住院死亡率的影响。
我们利用日本大阪一家高级重症监护中心的数据进行了一项回顾性观察研究。该研究纳入了2020年3月1日至2023年5月7日期间在该中心住院的1381例COVID-19患者,此时COVID-19在日本尚未成为五类传染病。排除18岁以下个体和孕妇。我们将患者分为两组:奥密克戎流行前组和奥密克戎流行后组。研究的主要终点是住院死亡率,并比较两组中糖尿病对预后的影响。
Kaplan-Meier曲线显示,奥密克戎流行后组的住院死亡率显著低于奥密克戎流行前组。风险比(HR)为1.83(95%CI,1.36-2.50;p<0.0001)。在奥密克戎流行前组和流行后组中,糖尿病患者的住院死亡率均较高;其HR分别为1.39(95%CI,1.21-1.59;p<0.0001)和1.45(95%CI,1.15-1.83;p=0.0012)。糖尿病对奥密克戎流行后与住院死亡率之间的关联无显著交互作用(交互作用p=0.2154)。
由于奥密克戎亚毒株可能仍然流行,糖尿病未来可能继续导致COVID-19患者的住院死亡。